The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Myelodysplastic syndrome (MDS) and autoimmune diseases (AD): Hypomethylating agents to treat both.
Omar Al Ustwani
No relevant relationships to disclose
Laurie Ann Ford
No relevant relationships to disclose
Sheila N. J. Sait
No relevant relationships to disclose
Anne Marie W. Block
No relevant relationships to disclose
Maurice P. Barcos
No relevant relationships to disclose
Elizabeth A. Griffiths
Honoraria - Astex Therapeutics
Research Funding - Astex Therapeutics
James E. Thompson
No relevant relationships to disclose
Eunice S. Wang
No relevant relationships to disclose
Julian L. Ambrus
No relevant relationships to disclose
Meir Wetzler
No relevant relationships to disclose